Age and racial differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: A population-based study of 70,345 men

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Zhang, Hong ^a   Messing, Edward M ^a   Travis, Lois B ^a   Hyrien, Ollivier ^a   Chen, Rui ^a   Milano, Michael T ^a   Chen, Yuhchyau ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Age; Population study; Prostate cancer; Race; Screen detected; SEER

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CANCER STAGING; DISEASE CLASSIFICATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSTATE CANCER; RACE DIFFERENCE; SOCIAL STATUS; VERY ELDERLY;

EID: 84892415984     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00312     Document Type: Article

References (48)

1. SEER Stat Facts Sheet: Cancer of the Prostate. Available from: www.seer.cancer.gov/statfacts/html/prost.html.
2. Peres J. New PSA guidelines discourage overscreening. J Natl Cancer Inst (2012) 104:8-9. doi:10.1093/jnci/djr539.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 360:1320-8. doi:10.1056/NEJMoa0810084.
4. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, Seventh Edition. New York: Springer Science+Business Media (2009).
5. Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol (1996) 155:821-6. doi:10.1097/00005392-199603000-00005.
6. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol (1997) 157:2206-9. doi:10.1016/S0022-5347(01)64719-0.
7. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol (1999) 161:1525-9. doi:10.1016/S0022-5347(05)68944-6.
8. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 24:3973-8. doi:10.1200/JCO.2005.04.0756.
9. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 174:903-7. doi:10.1097/01.ju.0000169475.00949.78.
10. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys (1997) 37:1043-52. doi:10.1016/S0360-3016(96)00590-1.
11. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 71:3582-93. doi:10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y.
12. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology (1994) 43:828-33. doi:10.1016/0090-4295(94)90144-9.
13. Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Urology (2004) 64:84-9. doi:10.1016/j.urology.2004.02.004.
14. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (1995) 154:1818-24. doi:10.1097/00005392-199511000-00063.
15. Lowe BA, Lieberman SF. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol (1997) 158:1452-6. doi:10.1097/00005392-199710000-00036.
16. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 281:1591-7. doi:10.1001/jama.281.17.1591.
17. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol (1994) 152(5 Pt 2):1837-42.
18. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer (2002) 95:281-6. doi:10.1002/cncr.10657.
19. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 280:969-74. doi:10.1001/jama.280.11.969.
20. Zhang H, Travis LB, Chen R, Hyrien O, Milano MT, Newlands SD, et al. Impact of radiotherapy on laryngeal cancer survival: a population-based study of 13,808 US patients. Cancer (2012) 118:1276-87. doi:10.1002/cncr.26357.
21. Werner CA. The Older Population 2010: 2010 Census Briefs. U.S. Census Bureau, U.S. Department of Commerce, Economics and Statistics Administration. (2011). Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf.
22. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer (2012) 118:3062-70. doi:10.1002/cncr.26392.
23. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2011) 29:235-41. doi:10.1200/JCO.2010.30.2075.
24. Delongchamps NB, Wang CY, Chandan Y, Jones RF, Threatte G, Jumbelic M, et al. Pathological characteristics of prostate cancer in elderly men. J Urol (2009) 182:927-30. doi:10.1016/j.juro.2009.05.018.
25. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol (1999) 162:1346-51. doi:10.1016/S0022-5347(05)68282-1.
26. Wells TS, Bukowinski AT, Smith TC, Smith B, Dennis LK, Chu LK, et al. Racial differences in prostate cancer risk remain among US servicemen with equal access to care. Prostate (2010) 70:727-34. doi:10.1002/pros.21105.
27. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer (2006) 107:75-82. doi:10.1002/cncr.21954.
28. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 38:652-8. doi:10.1038/ng1808.
29. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 39:631-7. doi:10.1038/ng1999.
30. Gaston KE, Kim D, Singh S, Ford OH III, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol (2003) 170:990-3. doi:10.1097/01.ju.0000079761.56154.e5.
31. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 68:927-36. doi:10.1158/0008-5472.CAN-07-2608.
32. Powell IJ, Zhou J, Sun Y, Sakr WA, Patel NP, Heilbrun LK, et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol (2004) 172:1848-52. doi:10.1097/01.ju.0000142779.76603.be.
33. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 46:3095-101. doi:10.1016/j.ejca.2010.09.016.
34. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 347:781-9. doi:10.1056/NEJMoa012794.
35. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 364:1708-17. doi:10.1056/NEJMoa1011967.
36. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 367:203-13. doi:10.1056/NEJMoa1113162.
37. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol (2009) 182:2702-7. doi:10.1016/j.juro.2009.08.026.
38. Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 298:1533-8. doi:10.1001/jama.298.13.1533.
39. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol (2008) 179:1775-9. doi:10.1016/j.juro.2008.01.016.
40. Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol (2008) 179:516-22. doi:10.1016/j.juro.2007.09.085.
41. Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, et al. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer. BJU Int (2012) 109:1489-94. doi:10.1111/j.1464-410X.2011.10583.x.
42. Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2001) 49:673-7. doi:10.1016/S0360-3016(00)01421-8.
43. D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2001) 49:679-84. doi:10.1016/S0360-3016(00)01423-1.
44. Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology (2002) 59:560-5. doi:10.1016/S0090-4295(01)01658-2.
45. D'Amico AV, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrzytzky O, et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2002) 53:581-7. doi:10.1016/S0360-3016(02)02797-9.
46. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology (2003) 61:742-7. doi:10.1016/S0090-4295(02)02525-6.
47. Greene KL, Elkin EP, Karapetian A, Duchane J, Carroll PR, Kane CJ, et al. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol (2006) 175:125-9. doi:10.1016/S0022-5347(05)00056-X.
48. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol (2001) 165:126-9. doi:10.1097/00005392-200101000-00031.